Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRXBiotechnology
+$0.07 today
- Market cap
- $445.14M
- Beta
- 1.48
- P/E (TTM)
- -8.5
- EPS (TTM)
- -$0.74
Volume 1.64M
Average 0.22M
Returns on capital
Eupraxia Pharmaceuticals Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-65.6%
avg -174.9%
ROIC
-66.5%
avg -38.2%
ROA
-62.5%
avg -159.1%
Analysis
ROA is currently the strongest return metric at -62.5% versus its period average of -159.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
James A. Helliwell FRCPC | Chief Executive Officer & Director | CAD 673.92K | 52 | — | — |
Jeymi Tambiah | Chief Medical Officer | CAD 578K | — | — | — |
Alexander John Rothwell | Chief Financial Officer | CAD 410.52K | 57 | — | — |
Paul Anthony Brennan | Chief Corporate Development Officer | CAD 362.54K | — | — | — |
Wajida Leclerc CHRP | Executive Vice President Corporate Services & People | — | 66 | — | — |
Jeffrey Millard | Executive Vice President of Technical Operations | — | 50 | — | — |
Alex Therien | Executive VP of R&D | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Eupraxia Pharmaceuticals Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about EPRX's management, answered from reported figures.
Who manages EPRX?
Eupraxia Pharmaceuticals Inc. (EPRX) lists 7 active executives. The top listed executive is Paul Anthony Brennan, Chief Corporate Development Officer.
Continue the stock analysis
Jump to another research area for this company.